IPA (ImmunoPrecise Antibodies) (NASDAQ:IPA) has announced the development of a new class of GLP-1 therapies—leveraging AI—to enhance the efficacy, safety, and longevity of treatments for Type 2 diabetes (T2D) and obesity.
According to IPA, the new GLP-1 therapies were created using its LENS platform, an AI-driven system that analyzes evolutionary patterns in biological data. These AI-generated sequences have been meticulously optimized to maximize therapeutic performance while enhancing the patient experience. Key improvements include increased patentability, extended stability and resistance to degradation, improved administration routes for greater compliance, reduced dosing requirements, and more efficient manufacturing methods.
The company states that its GLP-1-like alternatives are currently under evaluation for potential transdermal delivery as non-invasive substitutes for injections. These constructs represent IPA’s first fully AI-generated assets, complementing its expanding portfolio of laboratory-developed therapies.
